Adam H Schechter Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 days, 5 hours ago
Adam H Schechter has an estimated net worth of at least $22.6 million*, as of Nov. 27, 2024. They own 87,441 shares of LH stock. They have sold 6,189 shares of LH stock since 2021, for an estimated $1.5 million.
Adam H Schechter $LH SEC Form 4 Insider Trading
Adam H Schechter has filed a total of 1 insider trades in $LH since 2021. Their most recent trade was a sale of 6,189 shares, made on Nov 11, 2024. Their largest trade was a sale of 6,189 shares, made on Nov 11, 2024. We estimate that they now own 87,441 shares of $LH, worth an estimated $21.1 million.
Insider Trading at $LH
There have been a total of 74 insider trades reported at $LH since 2021, with 3,586 shares purchased and 204,204 shares sold. The most active insider traders in $LH stock have been Der Vaart Sandra D Van, Glenn A Eisenberg, and Mark S Schroeder. The most recent trade was a sale of 3,671 shares reported by Amy B. Summy (EVP, Chief Marketing Officer), made on Nov 22, 2024.
History of Insider Stock Trades by Adam H Schechter
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
LH
|
Sale | 6,189 | Nov 11, 2024 | Nov. 13, 2024, 9:16 a.m. |
$LH Executives and Stock Owners with Insider Trades
-
Der Vaart Sandra D Van, EVP, Chief Legal Officer
-
Glenn A Eisenberg, Chief Financial Officer, EVP
-
Mark S Schroeder, EVP, President-Diagnostics Lab
-
Peter J Wilkinson, SVP, Chief Accounting Officer
-
Amy B. Summy, EVP, Chief Marketing Officer
-
Mark S Schroeder, EVP, Pres Diagnostics & COO
-
Brian J Caveney, EVP, President of Diagnostics
-
Lance Berberian, EVP, CIO & CTO
-
Paul R Kirchgraber, CEO, Covance Drug Development
-
Adam H Schechter, President & CEO
-
Jonathan P. Divincenzo, EVP, Pres, Central Labs & Intl
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.